Novavax CEO to Present at Phacilitate Vaccine Forum Barcelona 2010
ROCKVILLE, Md., June 18 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage vaccine company, announced today that Dr. Rahul Singhvi, President and Chief Executive Officer, will be presenting at the Phacilitate Vaccine Forum Barcelona 2010 conference on June 21 and June 22, 2010 at The Fira Palace, Barcelona, Spain. Dr. Singhvi is participating in the roundtable discussion, 'Getting ready for the next influenza pandemic: How are recent experiences informing ongoing preparedness strategies?' and will also be speaking on the Case Study: 'Update on novel vaccine technologies and platforms that have been developed for the influenza market.'
Novavax, Inc. is a clinical-stage biopharmaceutical company creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like-particle (VLP) technology. The company produces potent VLP-based, recombinant vaccines utilizing new and efficient manufacturing approaches. Novavax is committed to using its VLP technology to create country-specific vaccine solutions. In 2009, Novavax launched a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India. Additional information about Novavax is available on the company's website: